Clinical trials
Lung Diseases clinical trials
Below are recruiting lung diseases clinical trials, each written for real people, not researchers. We’re tracking 426 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06522334Recruiting
Lung disease registry study in Austria
This study collects information from people with interstitial lung disease in Austria to learn more about the condition and how it progresses. It does not involve any experimental treatment.
ViennaAges 18 years+ - NCT07366034RecruitingPhase 3
Testing nerandomilast for children with lung scarring
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Los Angeles, CaliforniaAges 2–17 - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Los Angeles, CaliforniaAges 18 years+ - NCT06549231RecruitingPhase 3
Rituximab and mycophenolate for scleroderma lung disease
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
ToursAges 18–100 - NCT07666841Recruiting
Home-based pulmonary rehab for chronic lung disease
This study tests whether a home-based pulmonary rehabilitation program using a smartphone or computer works as well as in-person rehab for people with chronic lung diseases like COPD or lung scarring. It aims to help you breathe better and feel stronger from home.
AshkelonAges 18 years+ - NCT07345052Recruiting
Study on systemic sclerosis in western Sweden
This study is looking at people with systemic sclerosis (a condition that causes hardening and tightening of the skin and can affect internal organs) to learn more about the disease. You may join if you have been diagnosed with this condition and meet a few other requirements.
Gothenburg, SwedenAges 18 years+ - NCT04896138Enrolling by invitation
Natural history study for lung scarring patients
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
Charlottesville, VirginiaAges 18 years+ - NCT07489066RecruitingPhase 2
Study of PF-08634404 for early-stage or locally advanced lung cancer
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Huntsville, AlabamaAges 18 years+ - NCT07384897Recruiting
Immune cells in lung cancer and chronic lung disease
This study looks at how immune cells work in lung cancer and chronic lung diseases. It aims to find better ways to treat these conditions by studying immune cells from blood, bone marrow, or lung samples.
BrusselsAges Up to 80 years - NCT05525312Recruiting
Two breathing strategies during lung surgery for lung cancer
This trial compares two ways of managing breathing while you have surgery to remove lung cancer. It may help doctors figure out which strategy is safer and works better during the operation.
MontpellierAges 18 years+ - NCT07516379Recruiting
Understanding Lung Rejection After Transplant
This study follows people with serious lung disease before and after lung transplant to understand how rejection happens and what warning signs to watch for. By studying your blood, tissue samples, and imaging, researchers hope to better predict and prevent transplant rejection.
Bethesda, MarylandAges 18–75 - NCT02852928Recruiting
ChILD-EU registry for childhood lung disease samples
This trial builds a European “registry and biobank” of children with suspected or confirmed interstitial lung disease (a type of lung problem), as well as conditions that can look similar. It helps researchers learn more about these rare childhood lung diseases and connect families to future studies.
Hanover, Lower SaxonyAges Any age - NCT07234032RecruitingPhase 3
Long-term follow-up study of TPIP for PH-ILD
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Naples, FloridaAges 18 years+ - NCT07179380RecruitingPhase 3
Inhaled treprostinil for pulmonary hypertension related to interstitial lung disease
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
Phoenix, ArizonaAges 18 years+ - NCT06998706RecruitingPhase 1
Testing patient's own lung stem cells for ILD
This study tests whether a patient's own lung stem cells can be used to repair damaged lungs in people with interstitial lung disease. It is an early-stage trial to see if the treatment is safe and may help improve breathing.
Qionghai, HainanAges 40–75 - NCT05051254Recruiting
Breathing muscle testing in children with breathing muscle weakness
This study looks at how hard it is for children to breathe and how their breathing muscles work, using specific breathing-related tests. It may help doctors better understand breathing problems and choose care more effectively.
ParisAges birth–17 years - NCT06082401Recruiting
Adding filtering to improve donor lungs
This trial tests whether adding a special filtering treatment (hemodiafiltration) during the lung reconditioning process (EVLP) can help improve marginal donor lungs before transplant. It aims to see if more lungs can be used for patients waiting for a transplant.
ViennaAges Any age - NCT05798923RecruitingPhase 2
Study of a new drug for pulmonary hypertension with lung disease
This trial tests an investigational drug called LAM-001 for people who have pulmonary hypertension (high blood pressure in the lungs) along with a type of lung disease called interstitial lung disease. The drug may help improve symptoms and daily function. This study will see if the drug is safe and helpful for this condition.
Tucson, ArizonaAges 18–85 - NCT02270476Recruiting
Study of how cystic fibrosis lung disease changes over time
This observational study follows children newly diagnosed with cystic fibrosis to understand how their lung disease develops. It may help doctors better predict disease course and choose the right timing for care.
Heidelberg, Baden-WurttembergAges Any age - NCT06476470Recruiting
Taiwan ILD registry for understanding lung disease
This registry is gathering information from people with different types of interstitial lung disease (ILD) across Taiwan. It aims to better understand the disease and improve future care.
TaichungAges 18 years+ - NCT07406932Recruiting
JAK inhibitors vs standard therapy for lung scarring in Anti-Synthetase Syndrome
This trial tests whether a new class of drugs called JAK inhibitors (which block inflammation signals) is better than a standard treatment (calcineurin inhibitors) for people with lung scarring (interstitial lung disease) caused by Anti-Synthetase Syndrome. It is for people who have not yet taken any immune-suppressing medications for this condition.
Beijing, Beijing MunicipalityAges 18–75 - NCT06855004Recruiting
Study of severe breathing problems in people with lung scarring
This study follows patients with chronic lung scarring (fibrosing interstitial lung disease) who are in the intensive care unit for severe breathing failure. It aims to better understand their condition and care, which may help improve future treatments.
BobignyAges 18 years+ - NCT05678166Recruiting
Testing a blood marker to predict worsening lung mycobacterial disease
This study checks whether a blood test called soluble programmed death-1 can help predict how nodular-bronchiectatic nontuberculous mycobacterial (NTM) lung disease will progress. Results may help doctors monitor patients more accurately and decide when to treat or follow more closely.
TaipeiAges 20 years+ - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung diseases?
- Yes. Clin2 currently lists 426 recruiting lung diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.